Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | COMT | P21964 | 1/20 | 0.62 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 3/20 | 0.36 |
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 4/20 | 0.36 |
| ▸ | TTR | P02766 | 1/20 | 0.35 |
| ▸ | ERN1 | O75460 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1446844 | 0.93 | COMT (0.56) | COMTS1PR1NPC1RAB9AMAPT | |
| SCHEMBL1446692 | 0.87 | COMT (0.54) | COMTS1PR1NPC1RAB9AMAPT | |
| SCHEMBL1446978 | 0.87 | COMT (0.56) | COMTS1PR1NPC1RAB9AMAPT | |
| SCHEMBL1447772 | 0.86 | COMT (0.47) | COMTRAB9AMAPTTTRERN1 | |
| SCHEMBL1447153 | 0.86 | COMT (0.47) | COMTMAPTTTRERN1HPGD | |
| SCHEMBL1448018 | 0.85 | COMT (0.44) | COMTMAPTTTRHPGDMAPK1 | |
| SCHEMBL1446781 | 0.84 | COMT (0.54) | COMTS1PR1NPC1RAB9AMAPT | |
| SCHEMBL3588577 | 0.83 | COMT (0.55) | COMTS1PR1NPC1RAB9AMAPT | |
| SCHEMBL1447379 | 0.83 | COMT (0.49) | COMTS1PR1NPC1RAB9AMAPT | |
| SCHEMBL1446737 | 0.83 | COMT (0.44) | COMTMAPTTTRERN1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1907382-B1 | NITROCATECHOL DERIVATIVES AS COMT INHIBITORS | BIAL PORTELA & CA SA (PT) | 2015-05-27 | — | — | EP | claimed |
| US-20150072977-A1 | NITROCATECHOL DERIVATIVES AS COMT INHIBITORS | BIAL - PORTELA & CA, S.A. (PT) | 2015-03-12 | — | — | US | claimed |
| US-8168793-B2 | Nitrocatechol derivatives as COMT inhibitors | PORTELA & CA., S.A. (PT) | 2012-05-01 | — | — | US | claimed |
| EP-2301934-A1 | Nitrocatechol derivatives as COMT inhibitors | BIAL - Portela & Ca., S.A. (PT) | 2011-03-30 | — | — | EP | claimed |
| US-20090054437-A1 | Nitrocatechol Derivatives as Comt Inhibitors | PORTELA & CA., S.A. (PT) | 2009-02-26 | — | — | US | claimed |
| EP-1907382-A1 | NITROCATECHOL DERIVATIVES AS COMT INHIBITORS | Portela & C.A. S.A (PT) | 2008-04-09 | — | — | EP | claimed |
| WO-2007013830-A1 | NITROCATECHOL DERIVATIVES AS COMT INHIBITORS | PORTELA & CA. S.A. (PT) | 2007-02-01 | — | — | WO | claimed |
| US-20220388999-A1 | NITROCATECHOL DERIVATIVES AS COMT INHIBITORS | BIAL PORTELA & CA SA (PT) | 2022-12-08 | — | — | US | disclosed |
| US-20200102295-A1 | NITROCATECHOL DERIVATIVES AS COMT INHIBITORS | BIAL - PORTELA & CA, S.A. (PT) | 2020-04-02 | — | — | US | disclosed |
| US-10336740-B2 | Nitrocatechol derivatives as COMT inhibitors | BIAL—PORTELA & CA, S.A. (PT) | 2019-07-02 | — | — | US | disclosed |
| US-20170362213-A1 | NITROCATECHOL DERIVATIVES AS COMT INHIBITORS | PORTELA & COMPANHIA, S.A. (PT) | 2017-12-21 | — | — | US | disclosed |
| US-9745290-B2 | Dosage regimen for COMT inhibitors | BIAL—PORTELA & CA, S.A. (PT) | 2017-08-29 | — | — | US | disclosed |
| EP-2124947-B1 | DOSAGE REGIMEN FOR COMT INHIBITORS | BIAL - PORTELA & CA S A (PT) | 2017-07-19 | — | — | EP | disclosed |
| EP-2301934-A1 | Nitrocatechol derivatives as COMT inhibitors | BIAL - Portela & Ca., S.A. (PT) | 2011-03-30 | — | — | EP | disclosed |
| US-20100113529-A1 | DOSAGE REGIMEN FOR COMT INHIBITORS | BIAL-PORTELA & CA., S.A. | 2010-05-06 | — | — | US | disclosed |
| EP-2124947-A1 | DOSAGE REGIMEN FOR COMT INHIBITORS | BIAL - Portela & Ca., S.A. (PT) | 2009-12-02 | — | — | EP | disclosed |
| US-20090054437-A1 | Nitrocatechol Derivatives as Comt Inhibitors | PORTELA & CA., S.A. (PT) | 2009-02-26 | — | — | US | disclosed |
| WO-2008094053-A1 | DOSAGE REGIMEN FOR COMT INHIBITORS | BIAL-PORTELA & CA, S.A. (PT) | 2008-08-07 | — | — | WO | disclosed |
| EP-1907382-A1 | NITROCATECHOL DERIVATIVES AS COMT INHIBITORS | Portela & C.A. S.A (PT) | 2008-04-09 | — | — | EP | disclosed |
| WO-2007013830-A1 | NITROCATECHOL DERIVATIVES AS COMT INHIBITORS | PORTELA & CA. S.A. (PT) | 2007-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113529-A1 | DOSAGE REGIMEN FOR COMT INHIBITORS | COMT, CYP3A43, CYP2D6 | COMT 1/4885S1PR1 3827/4885NPC1 2414/4885 |
| US-20170362213-A1 | NITROCATECHOL DERIVATIVES AS COMT INHIBITORS | COMT, PNMT, OPRK1 | COMT 1/4885S1PR1 4343/4885NPC1 470/4885 |
| US-20150072977-A1 | NITROCATECHOL DERIVATIVES AS COMT INHIBITORS | COMT, PNMT, OPRK1 | COMT 1/4885S1PR1 4343/4885NPC1 470/4885 |
| US-20220388999-A1 | NITROCATECHOL DERIVATIVES AS COMT INHIBITORS | COMT, PNMT, OPRK1 | COMT 1/4885S1PR1 4357/4885NPC1 504/4885 |
| US-20090054437-A1 | Nitrocatechol Derivatives as Comt Inhibitors | COMT, PNMT, OPRK1 | COMT 1/4885S1PR1 4343/4885NPC1 470/4885 |
| US-10336740-B2 | Nitrocatechol derivatives as COMT inhibitors | COMT, PNMT, OPRK1 | COMT 1/4885S1PR1 4343/4885NPC1 470/4885 |
| US-20200102295-A1 | NITROCATECHOL DERIVATIVES AS COMT INHIBITORS | COMT, PNMT, OPRK1 | COMT 1/4885S1PR1 4357/4885NPC1 504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.